Medical Device Division Of MHLW Approves DVX’s Pacemaker/Defibrillator Lead Extracting Kit
This article was originally published in PharmAsia News
The medical device division of the Pharmaceutical and Food Sanitation Council, Ministry of Health, Labor and Welfare approved Japanese medical device company DVX' Pacemaker/Defibrillator Lead Extracting Kit. On the same day, the division designated cultured corneal epithelial cell sheets by Kobe-based biology company Arblast as an orphan disease-treating medical device. The sheet is used to treat complications of Stevens Johnson Syndrome and corneal epithelial cell fatigue. Clinical trials will start early next year in Japan. (Click here for more - Japanese language
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.